Study backs prophylactic COVID-19 therapies in severe immunosuppression
Patients who fail to respond to vaccination could benefit from a 'timely' monoclonal antibody combination, a French study suggests
Patients with immune-mediated inflammatory diseases could be given prophylactic anti-SARS-CoV-2 monoclonal antibodies to lower their risk of severe disease, say French researchers.
Results from their world-first study published in The Lancet Rheumatology suggest that one third of severely immunocompromised individuals fail to mount an adequate humoral response to vaccination.
